VeriMomIst myricetin sesquicaprylate in der Schwangerschaft sicher?
No harmonised CLP classification, no SCCS/CIR reproductive safety assessment located for this ingredient, and the parent compound myricetin lacks consistent evidence of human teratogenicity; published literature on myricetin mainly reports biological activity and some protective/reparative effects in animal models rather than reproductive hazard. Topical esters are expected to have low but measurable dermal absorption; therefore exposure during pregnancy is low but not nil. (Sources: PubMed review on myricetin; cosmetic ingredient databases listing myricetin sesquicaprylate; EWG myricetin page).
Related ingredients
Frequently asked questions
- Ist myricetin sesquicaprylate in der Schwangerschaft sicher?
- No harmonised CLP classification, no SCCS/CIR reproductive safety assessment located for this ingredient, and the parent compound myricetin lacks consistent evidence of human teratogenicity; published literature on myricetin mainly reports biological activity and some protective/reparative effects in animal models rather than reproductive hazard. Topical esters are expected to have low but measurable dermal absorption; therefore exposure during pregnancy is low but not nil. (Sources: PubMed review on myricetin; cosmetic ingredient databases listing myricetin sesquicaprylate; EWG myricetin page).
- Ist myricetin sesquicaprylate während des Stillens sicher?
- No data found showing reproductive or lactation-specific toxicity or harmonised classification for myricetin sesquicaprylate. Dermal use in nursing parent is expected to give low but measurable exposure; transfer into breastmilk after topical use is unlikely but not studied for this ester specifically.
- Ist myricetin sesquicaprylate sicher für Babyhaut?
- No infant-specific safety studies located for the sesquicaprylate ester. Because infants (0–3 yr) have higher skin permeability and surface‑area‑to‑weight ratio, exposure score is increased by +1 compared with adults (adult e=1 → infant e=2). No evidence was found to indicate the ingredient is a developmental toxin or endocrine disruptor at expected topical exposures.
- Wie bewertet VeriMom myricetin sesquicaprylate?
- VeriMom bewertet myricetin sesquicaprylate mit 93/100 (keine bekannten Risiken) basierend auf EU CosIng, ECHA-Klassifizierungen und PubMed-Studien.
- Was sind schwangerschaftssichere Alternativen zu myricetin sesquicaprylate?
- Siehe unsere kuratierte Liste der schwangerschaftssicheren Alternativen zu myricetin sesquicaprylate basierend auf ähnlicher Funktion.
Prüfe jede Zutatenliste in 2 Sekunden
Lade VeriMom kostenlos — scanne jedes Produkt und sieh sofort die Schwangerschafts-Sicherheitsbewertung.
Medizinischer Haftungsausschluss
Diese Informationen dienen ausschließlich Bildungszwecken und stellen keine medizinische Beratung dar. Sicherheitsbewertungen basieren auf öffentlich zugänglichen Daten und spiegeln möglicherweise nicht alle Risiken wider. Konsultieren Sie immer Ihren Arzt, bevor Sie ein Produkt während der Schwangerschaft oder Stillzeit verwenden.